About
Ligand Traps for Diseases of High Unmet Medical Need
Areas of Focus
Categories
Biologics & Biopharmaceutical
Team (15)
Aaron Royston
Director
35Pharma
team_member
Caroline McNicoll
VP, General Counsel
35Pharma
team_memberexecutive
Dmitry Tikhomirov
EVP, Finance & Operations
35Pharma
team_member
George Georges
Chief Medical Officer
35Pharma
team_memberexecutive
Gilles Tremblay
VP, Preclinical & Discovery
35Pharma
team_memberexecutive
Gregg Beloff
Director
35Pharma
team_member
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
5
As Collaborator
0
Total Enrollment
153
By Phase
PHASE1: 5
By Status
NOT_YET_RECRUITING: 2TERMINATED: 2RECRUITING: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT07143448Lead Sponsor
A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults
PHASE1Not yet recruiting
40 participants
Started: Oct 31, 2025 · Completed: Jan 31, 2028
NCT07123779Lead Sponsor
Study of HS235 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (HFpEF)
PHASE1Not yet recruiting
40 participants
Started: Sep 30, 2025 · Completed: Sep 30, 2028
NCT06581159Lead Sponsor
Study of HS135 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
PHASE1Terminated
4 participants
Started: Jan 23, 2025 · Completed: Jul 29, 2025
NCT06714825Lead Sponsor
Study of HS235 for Assessing the Pharmacokinetics, Safety, and Pharmacodynamics in Overweight/Obese Healthy Subjects
PHASE1Recruiting
64 participants
Started: Nov 28, 2024 · Completed: Dec 31, 2025
NCT06493461Lead Sponsor
A Study of HS135 for the Treatment of Pulmonary Arterial Hypertension in Adults
PHASE1Terminated
5 participants
Started: Oct 23, 2024 · Completed: Mar 31, 2025
Locations (1)
Headquarters
Montreal, QC, Canada
Map
Loading map...